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Sex steroid hormones and brain function: PET imaging as a tool 
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ory,2	 anxiety-	related	 behaviour3	 and	 other	 functions	 at	 the	 cellular	
level.4 Sex steroid hormones are mainly synthesised by the ovaries 
and	 testis.	 The	 hypothalamic-	pituitary-	gonadal	 (HPG)	 axis	 is	 the	
main	 system	by	which	 the	production	and	 release	of	 sex	steroids	 is	
regulated.5	 Circulating	 sex	 hormones	 can	 stimulate	 the	 release	 of	
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided the original work is properly cited.
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gonadothropin-	release	hormones	(GnRH)	at	the	hypothalamus.	GnRH	
induces	the	release	of	luteinising	hormone	(LH)	and	follicle-	stimulating	
hormone	 (FSH)	 in	 the	pituitary,	which	activate	 the	 secretion	of	 ste-
roidal	 sex	 hormones	 from	 the	 gonads	 (Figure	1A).	 Peripheral	 sex	




These	 globulins	 protect	 steroid	 hormones	 against	 metabolic	 degra-





brain	because	 the	brain	 itself	 contains	 the	enzymes	needed	 for	 the	
















steroid receptors is already widely used in oncology to visualise recep-
tor	expression	and	receptor	occupancy	in	hormone-	sensitive	tumours	
such as breast and prostate cancer.14	 By	 contrast,	 sex	 hormone	 re-
ceptor	imaging	in	the	brain	is	still	in	its	infancy.15 Sex steroid receptor 
imaging	in	neuroscience	suffers	from	some	additional	hurdles,	such	as	
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In	this	review,	we	survey	the	available	literature	about	the	use	of	
PET	imaging	in	the	field	of	neuroendocrinology,	in	which	imaging	data	








2  | SEX STEROID HORMONES AND 
BRAIN FUNCTION
Oestrogens	 can	 exert	 their	 effects	 through	 either	 intracellular	 or	
membrane-	associated	 oestrogen	 receptors	 (ERs);	 in	 particular,	 the	
intracellular receptors ERα and ERβ,	 and	 membrane-	associated	 G-	





dition	 to	 this	 genomic	 signalling	 pathway,	 sex	 steroids	 can	 act	 via	







mans.18 Women are vulnerable to depression when the concentration 
of	 sex	hormones	 changes	markedly.	This	 can	 lead	 to	pre-	menstrual	
dysphoric	 disorder,	 post-	partum	 depression	 and	 perimenopausal	 or	
postmenopausal depression.19	 Oestrogens	 have	 antidepressant	 ef-
fects	 when	 they	 are	 administered	 either	 alone	 or	 in	 combination	
with antidepressants20,21	 and,	 consequently,	 oestrogen	 replacement	
therapy	can	be	used	to	prevent	the	development	of	depression	in	in-






tive	 effects	 of	 oestrogens	 on	 cognition.27-29	 In	Alzheimer’s	 disease,	
oestrogens have been shown to protect neurones against the toxic-
ity	of	amyloid	plaques.30	Nevertheless,	more	studies	are	necessary31 
because	 investigators	 from	 the	Women’s	 Health	 Initiative	Memory	
Study	found	that	therapy	with	a	combination	of	oestrogen	and	pro-
gestin	increased	the	risk	for	dementia	in	postmenopausal	women	and	
did	not	improve	their	performance	in	mild	cognitive	tasks.32 For this 
reason,	the	contribution	of	oestrogens	and	the	molecular	dynamics	of	
their interaction with other hormones and neurotransmitters should 
be	determined	to	obtain	a	better	understanding	of	the	role	of	these	
steroids	in	brain	function	and	neuroprotection.
Progestins	can	exert	 their	effects	 through	both	 intracellular	pro-
gestin	 receptors	 (PR-	A	and	PR-	B)	and	membrane-	associated	PRs.	 In	
addition,	 these	 neuroactive	 steroids	 can	 also	 interact	 with	 several	




can	 be	 neuroprotective	 because	 it	 attenuates	 the	 NMDA-	induced	
influx	of	Ca2+	via	 the	NMDA	receptor	 ion	channel.36 Progestins can 
also	interact	with	oestrogens	in	the	brain,	such	as	in	the	regulation	of	




gesterone	 in	 animal	models	 of	 traumatic	 brain	 injury	 and	 ischaemia	
can decrease the lesion volume in the brain42 and decrease cognitive 
deficits.43	Likewise,	progestins	can	exhibit	a	neuroprotective	effect	in	







drogens	 is	 related	 to	aggression.	An	excess	of	circulating	androgens	
induces	aggressive	behaviour	in	both	males	and	females.48	Androgens	
are	also	 involved	 in	depression	and	anxiety-	like	disorders,	especially	
after	 menopause	 in	 women	 and	 during	 hypogonadism	 in	 men.49 
Alterations	of	testosterone	 levels	were	associated	with	an	 increased	
risk	of	mood	disorders	and	psychosis.50	Anabolic	abuse	and	hyper-	or	





of	 inducing	 the	 formation	of	 spine	 synapses,54 which appears to be 
mediated	by	NMDA	activity.55
3  | PET TRACERS FOR STEROID HORMONE 
RECEPTORS IN BRAIN RESEARCH
Despite	 the	 increasing	 knowledge	 on	 the	 roles	 of	 sex	 steroid	 hor-
mones,	many	aspects	of	the	functions	and	mechanisms	of	action	of	






mone receptors use either autoradiography or ex vivo tissue counting. 
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So	far,	only	a	few	studies	have	measured	the	 in	vivo	distribution	of	
steroid	 receptor	 ligands	 in	 rodents,	whereas	 imaging	 studies	 of	 the	
human brain are lacking.
The	most	frequently	used	PET	tracer	for	imaging	oestrogen	recep-
tors is 16α-[	18F]	 fluoro-	17ß-	oestradiol	 ([18F]FES).	 [18F]FES has been 
successfully	 used	 in	 both	 preclinical	 and	 clinical	 studies,	 mostly	 in	
breast cancer.56	 [18F]FES	was	 the	 first	 PET	 tracer	 to	 be	 applied	 for	
quantitative	ex	vivo	assessment	of	oestrogen	receptors	 in	the	brain.	
The	brain	of	 female	rats	was	dissected	and	radioactivity	 in	different	
brain areas was measured ex vivo with a γ	counter.	By	applying	dif-
ferent	distribution	times,	information	about	the	kinetics	of	the	tracer	
in the rat brain was obtained.16	Specific	binding	of	the	tracer	was	ob-
served	only	in	brain	regions	with	high	ER	density,	such	as	the	pituitary	
and	hypothalamus.	Specific	binding	could	be	quantified	both	by	equi-
librium and dynamic kinetic analysis.16	Two	years	later,	[18F]FES	PET	
was	successfully	used	to	identify	ER	expression	in	the	tumour	of	six	
patients with brain meningiomas.57	Later	studies,	 including	our	own,	
have	shown	that	[18F]FES	PET	is	able	to	detect	ER-	expression	in	brain	
metastases	of	ER-	sensitive	tumours	such	as	breast	cancer.
More	 than	 a	 decade	 after	 the	 experiments	 of	 Moresco	 et	al,57 
our group investigated whether ER in the rat brain could be quanti-




but	not	 in	other	parts	of	the	brain.58	Ovariectomy	resulted	 in	an	 in-
crease	 in	 tracer	 uptake	 in	 the	 pituitary	 and	 hypothalamus,	whereas	
administration	of	exogenous	oestradiol	decreased	[18F]FES uptake in 
these	regions,	indicating	that	tracer	uptake	was	sensitive	to	circulating	
oestrogens	 competing	 for	 the	binding	 site	of	 the	ER.	Driven	by	 the	
promising	results	in	rats,	we	performed	a	small	[18F]FES	PET	study	in	
healthy	volunteers.	In	postmenopausal	women,	[18F]FES	PET	showed	




ER	antagonist	 significantly	 reduced	 [18F]FES in the pituitary but not 





























PR	 in	 a	 large	 fraction	 of	 positive	 tumours.	 [18F]FENP	 uptake	 did	
not	 correlate	 with	 PR	 levels	 and	 the	 tumour-	to-	background	 ratio	
was low.61	Moreover,	 the	 tracer	was	 rapidly	metabolised	 not	 only	
in	 the	 liver	 and	 blood,	 but	 also	 by	 tumour	 cells.62	 Subsequently,	
tracers with increased metabolic stability have been developed and 
tested	for	imaging	of	PR	in	human	breast	cancer,	including	21-	[18F]
fluoro-	16α,17α-	[(R)-	(1′-	α-	furylmethylidene)-	dioxy]-	19-	norpregn-	4-	
ene-	3,20-	dione	 ([18F]FFNP)63	 and	 4-	[18F]fluoropropyl-	tanaproget	






for	PET	 imaging	of	 the	androgen	 receptors	was	20-	[18F]fluoromibo-
lerone	 ([18F]Fmib),	which	was	 tested	 in	 both	 rats	 and	baboons	with	
promising results.65,66	More	tracers	have	been	synthesised	and	tested	
as	markers	of	prostate	cancer,67	of	which	16ß-	[18F]fluorodihydrotes-





and its uptake in the brain is very low.69	This	results	in	a	poor	signal-	
to-	noise	ratio,	which	precludes	the	detection	of	AR	in	the	rat	brain.	By	
contrast	 to	 rats,	 humans	 express	 SHBG,	which	 can	protect	 steroids	
such	as	[18F]FDHT	from	metabolic	degradation.70	Despite	the	disap-
pointing	results	obtained	in	rats,	the	stabilising	effect	of	SHBG	in	men	






4  | PET IMAGING OF AROMATASE AS A 
BIOMARKER FOR OESTROGEN SYNTHESIS
Aromatase	 is	a	key	enzyme	in	the	biosynthesis	of	oestrogens;	 it	ca-
talyses	 the	 conversion	of	 testosterone	 into	oestradiol.71	Aromatase	
is	 expressed	 in	 a	wide	 variety	 of	 tissues,	 including	 ovaries,	 adipose	
tissue,	 skin,	 testicles,	muscle,	 liver	 and	 the	 central	 nervous	 system.	
Aromatase	 has	 been	 suggested	 as	 a	 biomarker	 for	 neuroprotection	
because	it	increases	the	local	levels	of	oestrogens	in	injured	neurones	
in the brain.72	Aromatase	is	not	expressed	constitutively	in	the	brain	
but can be induced by testosterone or dihydrotestosterone.73	Brain	
aromatase	 is	 involved	 in,	 amongst	 others,	 the	 regulation	 of	 sexual	
behaviour,	 emotional	 behaviour,	 aggression,	 cognition,	memory	 and	
neuroprotection,73	making	 this	enzyme	an	 interesting	 target	 for	 the	
study	of	sex	steroid	hormones	in	the	brain.
Tracers	 for	 aromatase	 are	 generally	 based	 on	 enzyme	 inhibi-
tors.	The	nonsteroidal	aromatase	inhibitor	[11C]vorozole is the most 








vorozole demonstrated increased aromatase levels in the bed nu-
cleus	of	the	stria	terminalis	and	the	pre-	optic	areas	of	rats	treated	
with	anabolic	 androgenic	 steroids,	 as	well	 as	 in	 the	hypothalamus	
of	macaque	monkeys	treated	with	these	steroids.76,77	[11C]vorozole 
PET	imaging	in	baboons	showed	that	the	menstruation	cycle	had	a	
significant	effect	on	 tracer	binding	 in	 the	brain.78	The	 first	human	
PET	study	with	[11C]vorozole	was	performed	in	2010,79 demonstrat-
ing	 the	 specificity	 and	 kinetics	 of	 this	 tracer	 in	 the	 human	 brain.	
This	study	was	followed	by	recent	studies	evaluating	the	radiation	
dosimetry	and	binding	kinetics	of	[11C]vorozole in healthy men and 
women.80,81




ing in the brain.82	A	 later	 study	 tested	 the	 tracer	 [11C]cetrozole in 
rhesus	monkeys.	In	this	subsequent	study,	[11C]cetrozole displayed 
better	selectivity	and	specificity,	as	well	as	a	higher	signal-	to-	noise	
ratio,	 than	 [11C]vorozole.	 Therefore,	 it	 was	 better	 suited	 for	 the	
quantitative	analysis	of	aromatase	expression	in	the	amygdala,	hy-
pothalamus and nucleus accumbens in monkeys.83	So	far,	however,	





uation in clinical studies to obtain more insight regarding the value 
of	 these	 tracers	 is	 required.	 If	 successful,	 this	 PET	 imaging	 could	
provide	a	new	impetus	for	clinical	trials	on	the	role	of	aromatase	in	
health	 and	disease.	The	 chemical	 structure	of	 radiotracers	 for	 sex	
hormone	receptors	and	aromatase	tested	 in	the	brain,	 is	shown	in	
Figure 3.
5  | USE OF PET TRACERS TO STUDY SEX 











5.1 | Impact of sex steroid hormones in cerebral 
blood flow
A	general	 approach	 for	 studying	 the	 impact	 of	 steroid	hormones	 is	
to	detect	activation	of	specific	brain	regions	by	measurement	of	the	





Only	a	 few	studies	have	applied	 [15O]H2O	PET	to	study	 the	 im-
pact	of	hormonal	changes	on	brain	activity	so	far.	[15O]H2O	PET	has	
been	used	 to	 investigate	 the	 effect	 of	 oestrogen	 replacement	 ther-
apy	 on	 the	 rCBF.	 Significant	 longitudinal	 differences	were	 found	 in	
rCBF	activation	patterns	during	cognitive	tasks	between	controls	and	
women on oestrogen replacement therapy.84,85	 In	particular,	oestro-
gen	 replacement	 users	 showed	 higher	 rCBF	 in	 the	 memory	 circuit	
hippocampus-	parahippocampal	 gyrus-	temporal	 lobe	 than	non-	users.	
In	another	study,	[15O]H2O	PET	was	used	to	investigate	the	effect	of	
endogenous	 testosterone	on	 the	 rCBF	 in	 elderly	men.86 Higher en-
dogenous	 testosterone	concentrations	were	 found	to	correlate	with	
a	higher	rCBF	in	brain	regions	associated	with	memory	and	attention.	
Recently,	 [15O]H2O	PET	was	used	 to	 investigate	 the	correlation	be-
tween	a	decreased	production	of	progesterone	and	oestradiol	by	the	
ovaries	 and	 hippocampal	working	memory,	 although	 no	 statistically	
significant	changes	in	blood	flow	were	found.87
Thus,	the	limited	number	of	available	studies	suggests	that	mea-
surement	 of	 the	 rCBF	 with	 [15O]H2O	 PET	 could	 be	 a	 useful	 tool	
for	 investigating	 the	 impact	 of	 sex	 steroid	 hormones	 on	 cognition.	
However,	a	disadvantage	of	[15O]H2O	PET	is	the	exposure	of	subjects	
to	 a	 radioactive	 substance.	 For	 many	 research	 questions,	 magnetic	
resonance	 imaging	 (MRI)	 techniques	 have	 now	 replaced	 [15O]H2O	
PET.	 Functional	 MRI	 using	 blood-	oxygen-	level	 dependent	 (BOLD)	
imaging	 is	a	 frequently	used	 technique	 for	measuring	 regional	brain	






5.2 | Brain metabolism and sex hormones: [18F]FDG
2-	Deoxy-	2-	[18F]fluoro-	d-	glucose	 ([18F]FDG)	 is	 the	 most	 frequently	
used	 radiotracer	 in	 PET	 imaging.	 Because	 the	metabolic	 properties	










to	 investigate	 the	 effect	 of	 sex	 steroid	 hormones	 on	 brain	 glucose	
metabolism.	The	first	study	 in	 this	specific	 field	aimed	to	determine	
the	neural	correlates	of	sexual	competition	in	male	rhesus	macaques.	
The	 study	 showed	 metabolic	 differences	 between	 male	 monkeys	
confronted	with	 threats	 to	 their	exclusive	sexual	access	 to	a	 female	
mate	and	controls.	The	differences	in	brain	glucose	metabolism	were	













corresponds to the tracer tested in the 
































[11C] letrozole[11C] vorozole [11C] cetrozole
[18F]FDHT
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[18F]FDG	PET	was	 also	 used	 in	 several	 human	 studies	 to	 inves-
tigate	 the	 effect	 of	 steroid	 hormones	 on	 brain	metabolism.	 Reiman	
et al92	measured	[18F]FDG	uptake	in	specific	brain	regions	of	female	
volunteers	 aiming	 to	 study	 the	 effect	 of	 circulating	 oestrogens	 on	
brain	 glucose	 metabolism.	 Different	 [18F]FDG	 distribution	 patterns	
were	observed	during	the	different	phases	of	the	menstrual	cycle.	In	
particular,	 a	 higher	 [18F]FDG	uptake	was	observed	 in	 thalamic,	 pre-
frontal,	temporoparietal	and	inferior	temporal	regions	during	the	mid-	
follicular	 phase,	 whereas	 the	 mid-	luteal	 phase	was	 associated	with	









with breast cancer. Changes in glucose metabolism were mainly ob-
served	 in	 the	 frontal	 lobe	 and	 the	 hippocampus.	 A	 small	 [18F]FDG	
PET	study	in	men	with	hypogonadism	investigated	the	effect	of	tes-
tosterone substitution therapy on brain glucose metabolism during a 
mental rotation test.94	In	4	out	of	6	subjects,	testosterone	substitution	
improved the mental rotation score and only these subjects showed 





Besides	 the	 investigation	 of	 regional	 glucose	 metabolism,	 it	 is	
possible to study the connectivity and network changes associ-
ated	with	steroid	hormone	 treatment	using	 [18F]FDG	PET.	Ottowitz	
et al95	 investigated	whether	 the	 connectivity	 of	 specific	 brain	 areas	
was	 associated	 with	 systemic	 hormone	 levels.	 They	 observed	 that	





ciated	 to	hormonal	 therapies.	 [18F]FDG	PET	was	 applied	 to	 investi-
gate	possible	neurobiological	factors	underlying	the	hot	flashes	as	a	
secondary	effect	of	hormone	adjuvant	treatment	in	breast	cancer	pa-
tients. Reduced glucose metabolism in the hypothalamus and insular 
cortex	was	found	to	be	a	predictor	of	the	development	of	hot	flashes.97 
Other	studies	investigated	the	risk	of	developing	neurocognitive	disor-
ders by hormone therapy in menopausal and postmenopausal women. 
Silverman et al98	 investigated	 the	 effect	 of	 oestrogen-	containing	
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Alzheimer’s	disease.99	[18F]FDG	PET	has	also	been	used	to	study	the	
correlation between brain metabolism and oestradiol brain levels in 
postmenopausal	women	with	Alzheimer’s	 disease.	 In	 a	 small	 study,	
a	 direct	 linear	 correlation	was	 found	 between	 hippocampal	 glucose	
metabolism	 and	 oestradiol	 levels	 in	 the	 cerebrospinal	 fluid.100	 [18F]
FDG	PET	was	 also	 able	 to	 reveal	 regional	 changes	 in	 brain	 glucose	
metabolism	 as	 a	 result	 of	 testosterone	 replacement	 therapy	 in	 two	
hypogonadal	patients	with	Alzheimer’s	disease.101	Furthermore,	[18F]
FDG	PET	was	able	to	demonstrate	a	compensatory	effect	of	testoster-
one administration on brain hypometabolism in women with anorexia 
nervosa.102	An	example	of	[18F]FDG	imaging	in	the	brain	is	provided	
in Figure 4.
5.3 | Sex steroid hormones and neurotransmitter 
activity regulation
Sex steroid hormones are known to participate in many developmen-
tal	and	 regulatory	processes	 in	 the	brain.	Most	of	 these	effects	are	
mediated by either direct actions on hormone receptors or by indirect 
modulation	of	other	neurotransmitter	systems.103







interactions between sex hormones and serotonin neurotransmission.
[11C]-	WAY100635	can	be	used	to	measure	the	expression	of	the	
5-	HTR1A subtype. Some studies have used this tracer to assess pos-
sible	 correlations	 between	 5HTR1A expression and circulating hor-
mone	concentrations	in	humans.	PET	imaging	with	[11C]-	WAY100635	




also	 showed	 that	 lateralisation	of	5-	HTR1A in language areas (hemi-
spheric	asymmetry)	 is	positively	correlated	with	plasma	levels	of	sex	
hormones.106	Other	PET	studies	with	[11C]-	WAY100635	have	shown	
that	increased	5HTR1A expression was associated with enhanced pro-
gesterone	 and	DHEA	 levels	 in	 pre-	 and	postmenopausal	women.107 
Sex	hormone	levels	were	found	to	be	correlated	with	test	scores	for	





tradiol alone or oestradiol + progesterone.109
Another	 receptor	 of	 interest	 is	 the	 5-	HTR2A.	 Longitudinal	 PET	
studies	 with	 the	 tracer	 [18F]altanserin	 showed	 increased	 5-	HTR2A 
binding	 in	 the	whole	brain	and	 in	 specific	brain	 regions	 (eg,	 the	hy-
pothalamus	 and	 cortex)	 of	 postmenopausal	 women	 that	 were	 first	
treated	with	oestradiol	 alone,	 and	were	 later	 treated	with	 the	 com-
bination	of	oestradiol	with	progesterone.110,111	Another	 study	using	
the same radiotracer showed a positive correlation between cortical 
[18F]altanserin	binding	and	levels	of	endogenous	oestradiol	in	men.112
A	 recent	 study	 used	 [11C]SB207145,	 a	 specific	 tracer	 for	 im-
aging	 of	 5-	HTR4.	 A	 negative	 correlation	 was	 observed	 between	
binding	of	 [11C]SB207145	to	5-	HTR4 receptors in the whole brain 
and both oestradiol and testosterone levels in healthy men.113 
Several	 studies	 used	 the	 radiolabelled	 serotonin	 precursor	 [11C]-	
5-	hydroxytryptophan	 ([11C]-	5-	HTP)	 and	 tracers	 for	 the	 serotonin	
transporter	 (SERT).	 [11C]5-	HTP	and	 [15O]H2O	were	used	 to	 inves-
tigate	 the	correlation	between	 regional	 serotonin	synthesis,	blood	
flow	and	the	levels	of	sex	hormones	and	symptoms	of	premenstrual	
dysphoria	in	women,	showing	an	inverse	correlation	between	men-
strual phase changes in plasma oestradiol levels and changes in the 
right-	to-	left	[11C]5-	HTP	uptake	ratios	in	the	dorsolateral	prefrontal	
cortex.114	Two	PET	imaging	studies	with	different	tracers	examined	
the	 interplay	between	 sex	hormones	 and	 the	 expression	of	 SERT,	
which	 is	 known	 to	 be	 related	 to	 brain	 processes	 affected	 in	 psy-
chiatric disorders.115 Frokjaer et al116	 investigated	the	 influence	of	
therapy	 with	 GnRH	 agonists	 on	 depressive	 symptoms	 and	 SERT	
availability	 using	 PET	 with	 the	 tracer	 [11C]DASB.	 GnRH	 therapy	







over	 the	different	phases	of	 the	menstrual	cycle	 in	healthy	women.	
However,	no	significant	changes	in	[11C]raclopride binding were ob-
served.118	Another	 study	 evaluated	 the	 effect	 of	 circulating	 testos-
terone	 and	 oestradiol	 on	 D2/D3	 receptor	 availability	 in	 Göttingen	
minipigs	treated	with	chronic	amphetamine	 in	a	 longitudinal	design,	
using	[11C]raclopride	PET.	The	study	did	not	reveal	any	significant	cor-
relation between the imaging results and the plasma concentrations 
of	testosterone	or	oestradiol	either.119	A	later	study	used	a	different	
tracer	 for	 the	 same	 receptor	 ([18F]fluoroclebopride)	 in	 female	cyno-
molgus	 monkeys	 and	 demonstrated	 differences	 in	 the	 distribution	
volume ratio in the caudate nucleus and the putamen between the 
luteal	and	follicular	phase.120	Two	additional	studies	on	the	dopami-
nergic	system	have	been	reported	upon.	Kindlundh	et	al121 used three 
different	 tracers	 to	measure	 dopaminergic	 changes	 in	 the	 rat	 brain	
as	a	result	of	 treatment	with	anabolic-	androgenic	steroids.	Changes	
in	 the	 density	 of	 dopamine	 transporters	were	 assessed	 using	 [11C]
FE-	β-	CIT,	changes	in	the	density	of	D1	receptors	were	assessed	with	
[11C]-	(+)-	SCH23390	and	changes	in	D2/D3	receptors	were	assessed	
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Interactions	of	steroid	hormones	with	the	GABAergic	neurotans-
mitter	 systems	 have	 been	 studied	 using	PET	with	 [18F]flumazenil,	 a	
tracer	for	GABAA	receptors.	The	effect	of	ovariectomy	and	oestradiol	
replacement	on	GABAA receptor expression was investigated in a social 
subordination	model	of	female	rhesus	monkeys.	Ovariectomy	caused	
an	 increase	 in	 [18F]flumazenil	 binding	 in	 the	 cortex	 and	 other	 brain	
areas.	This	effect	was	reversed	by	hormone	replacement	therapy.123











steroid hormone receptors in the brain has been demonstrated9 and 
some	roles	of	 these	hormones	 in	the	brain	have	been	elucidated,2-4 
there	is	still	a	large	gap	in	our	knowledge	of	these	hormone	system.	
This	can	be	partly	be	ascribed	to	the	lack	of	suitable	techniques	avail-
able	 for	assessing	 the	dynamics	and	 interplay	of	 these	molecules	 in	
the	living	brain.	Non-	invasive	imaging	could	offer	a	good	opportunity	
to	investigate	the	role	of	sex	steroid	hormones	and	their	receptors	in	
the brain in health and disease.
Specific	radiotracers	for	PET	imaging	of	oestrogen,	progestin	and	
androgen	receptors	have	been	developed,	although	only	few	of	them	












brain activity or examining the relationship between stress hormone 
levels	and	biological	outcomes	in	humans.	Studies	of	the	correlations	








various	 neurotransmitter	 systems.	These	 studies	 could	 help	 to	 un-
ravel	the	mechanisms	that	are	responsible	for	the	impact	of	sex	ste-
roid	hormones	on	brain	function	and	neuroprotection.	An	improved	
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